Variable expression of the disialoganglioside gd2 in breast cancer molecular subtypes

Erber R, Kailayangiri S, Hübner H, Rübner M, Hartmann A, Häberle L, Meyer J, Völkl S, Mackensen A, Landgraf L, Geppert CI, Schulz-Wendtland R, Beckmann M, Fasching P, Farwick N, Rossig C, Gaß P (2021)

Publication Type: Journal article

Publication year: 2021

Journal

Cancers MDPI

Book Volume: 13

Article Number: 5577

Journal Issue: 21

DOI: 10.3390/cancers13215577

Abstract

The disialoganglioside GD2 is a tumor-associated antigen that may allow for the application of targeted immunotherapies (anti-GD2 antibodies, GD2 CAR T cells) in patients with neuroblastoma and other solid tumors. We retrospectively investigated GD2 expression in a breast cancer cohort, using immunohistochemistry (IHC) and immunofluorescence (IF) on tissue microarrays (TMAs), and its impact on survival. GD2 expression on IHC (n = 568) and IF (n = 503) was investigated in relation to subtypes and patient outcome. Overall, 50.2% of the 568 IHC-assessed samples and 69.8% of the 503 IF-assessed samples were GD2-positive. The highest proportion of GD2-positive tumors was observed in luminal tumors. Significantly fewer GD2-positive cases were detected in triple-negative breast cancer (TNBC) compared with other subtypes. The proportion of GD2-expressing tumors were significantly lower in HER2-positive breast cancer in comparison with luminal tumors on IF staining (but not IHC). GD2 expression of IHC or IF was not significantly associated with disease-free or overall survival, in either the overall cohort or in individual subtypes. However, GD2 expression can be seen in more than 50% of breast cancer cases, with the highest frequency in hormone receptorpositive tumors. With this high expression frequency, patients with GD2-positive advanced breast cancer of all subtypes may benefit from GD2-targeting immunotherapies, which are currently subject to clinical testing.

Authors with CRIS profile

Ramona Erber Institute of Pathology Hanna Hübner Department of Obstetrics and Gynaecology Matthias Rübner Department of Obstetrics and Gynaecology Arndt Hartmann Lehrstuhl für Allgemeine Pathologie und Pathologische Anatomie Simon Völkl Department of Medicine 5 – Haematology and Oncology Andreas Mackensen Lehrstuhl für Innere Medizin V Carol-Immanuel Geppert Institute of Pathology Matthias Beckmann Lehrstuhl für Geburtshilfe und Frauenheilkunde Peter Fasching Professur für Translationale Frauenheilkunde und Geburtshilfe Paul Gaß Department of Obstetrics and Gynaecology

Involved external institutions

Universitätsklinikum Münster DE Germany (DE)

How to cite

APA:

Erber, R., Kailayangiri, S., Hübner, H., Rübner, M., Hartmann, A., Häberle, L.,... Gaß, P. (2021). Variable expression of the disialoganglioside gd2 in breast cancer molecular subtypes. Cancers, 13(21). https://dx.doi.org/10.3390/cancers13215577

MLA:

Erber, Ramona, et al. "Variable expression of the disialoganglioside gd2 in breast cancer molecular subtypes." Cancers 13.21 (2021).

BibTeX: Download